Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015

Matthew Herder, Andrea MacGregor, Audrey D. Zhang, Joshua D. Wallach, Joseph S. Ross

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Thirty days after a novel therapeutic agent, a new molecular entity, or original biologic is approved, the US Food and Drug Administration (FDA) must publicly disclose its approval package, including scientific reviews completed by FDA disciplines (eg, pharmacology, statistical, and medical reviewers) and any available assessments by agency leadership.1 Although reports of internal disagreement have surfaced,2 it is unclear how often such disagreements occur. Disagreements document differing points of view or engaged discussion and may, thus, capture important scientific debates or signal challenging decisions within the agency. We sought to determine the frequency of disagreements within the FDA regarding approval of novel therapeutic agents.

    Original languageCanadian English
    JournalArticles, Book Chapters, & Popular Press
    Publication statusPublished - Jan. 1 2020

    Keywords

    • Food and Drug Regulation
    • Regulatory Disagreements

    Disciplines

    • Food and Drug Law
    • Health Law and Policy
    • Law
    • Medical Jurisprudence
    • Science and Technology Law

    Fingerprint

    Dive into the research topics of 'Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015'. Together they form a unique fingerprint.

    Cite this